Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025British Journal of HaematologyOpen Access

Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSridhar ChagantiVDVaishali DulobdasMWMatthew R. Wilson

Discussion

Loading...

Member takes

Overview

Guidelines provide practical administration and toxicity management strategies for bispecific antibody therapy in lymphoma patients, highlighting CRS risks.

Key Points

  • Bispecific antibodies show promise in treating lymphoma with manageable side effects, particularly cytokine release syndrome (CRS).
  • Notable toxicity during treatment includes B-cell aplasia and increased infection risk, complicating patient management.
  • This guideline utilizes the GRADE framework to improve clinician guidance for the effective use of anti-CD3 × CD20 bispecific antibodies.
  • Prompt recognition and treatment of CRS are key, with comprehensive monitoring during the initial doses of bispecific antibody therapy.

Cite This Study

Chaganti et al. (2025) studied this question.

synapsesocial.com/papers/68c192579b7b07f3a0616e34https://doi.org/10.1111/bjh.70018
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium2025
  2. 2Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025 · 1 citations
  3. 3Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort2025
  4. 4Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma2025
  5. 5Real-world experience with management of CRS and ICANS following CD3xCD20 bispecific antibody therapy.2026